SPRAVATO® Nasal Spray Therapy
Experience a New Path Forward: SPRAVATO® for Depression Relief
What Is SPRAVATO®?
SPRAVATO® (esketamine) is a groundbreaking nasal spray approved by the FDA for adults struggling with two challenging types of depression:
Treatment-Resistant Depression (TRD): Designed for individuals who have not responded to at least two different antidepressants.
Major Depressive Disorder (MDD) with Acute Suicidal Ideation or Behavior: A rapid-acting option for individuals experiencing intense symptoms and an urgent need for stabilization.
Unlike traditional oral antidepressants that may take weeks to work, SPRAVATO® has been shown to deliver symptom relief in as little as 24 hours.
How SPRAVATO® Works
SPRAVATO® operates differently from standard treatments by acting on NMDA receptors in the brain. This novel approach helps reset neural pathways that contribute to depression. Administered in our certified treatment center at Three Rivers Mental Health, patients self-administer the nasal spray under clinical supervision and remain on-site for observation for a minimum of two hours to ensure safety.